Assessment of VEGF-D expression measured by immunohistochemical staining and F-18 FDG uptake on PET as biological prognostic factors for recurrence in patients with surgically resected lung adenocarcinoma

被引:6
|
作者
Zhang, Lina [2 ,3 ]
Higashi, Kotaro [1 ,2 ]
Ishigaki, Yasuhito [4 ]
Ueda, Yoshimichi [5 ]
Sakuma, Tsutomu [6 ]
Takegami, Tsutomu [1 ]
Oguchi, Manabu [7 ]
Xu, Ke [3 ]
Ohta, Yasuhiko [8 ]
Nishida, Hiroto [1 ]
Tonami, Hisao [2 ]
机构
[1] Asanogawa Gen Hosp, Dept Radiol, Kanazawa, Ishikawa 9208621, Japan
[2] Kanazawa Med Univ, Dept Radiol, Ishikawa, Japan
[3] China Med Univ, Dept Radiol, Affiliated Hosp 1, Liaoning, Peoples R China
[4] Kanazawa Med Univ, Med Res Inst, Ishikawa, Japan
[5] Kanazawa Med Univ, Dept Pathol, Ishikawa, Japan
[6] Kanazawa Med Univ, Dept Thorac Surg, Ishikawa, Japan
[7] Publ Cent Hosp Matto Ishikawa, Dept Radiol, Ishikawa, Japan
[8] Natl Hosp Org, Dept Thorac Surg, Kanazawa Med Ctr, Kanazawa, Ishikawa, Japan
关键词
VEGF-D; FDG PET; Lung adenocarcinoma; Lymph node metastasis; Recurrence; ENDOTHELIAL GROWTH-FACTOR; LYMPH-NODE METASTASIS; POSITRON-EMISSION-TOMOGRAPHY; COLORECTAL-CARCINOMA; CELL-CARCINOMA; CANCER; ANGIOGENESIS; RECEPTOR; LYMPHANGIOGENESIS; SURVIVAL;
D O I
10.1007/s12149-010-0392-8
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective To assess whether the combined evaluation of vascular endothelial growth factor D (VEGF-D) expression and fluorodeoxyglucose (FDG) uptake correlates with lymph node metastasis and post-operative recurrence in patients with lung adenocarcinoma. Methods Forty-six patients with lung adenocarcinomas, who had undergone both preoperative FDG PET imaging and thoracotomy, were enrolled in this study. The surgically resected tumor specimens were used to assess the protein levels of VEGF-D as measured by immunohistochemical assay. Results The patients were divided into the following four groups: those who were VEGF-D negative and had low FDG uptake (group I, 3 patients), VEGF-D positive and had low FDG uptake (group II, 20 patients), VEGF-D negative and had high FDG uptake (group III, 13 patients), and VEGF-D positive and had high FDG uptake (group IV, 10 patients). Lymph node metastases were seen only in group III. The 5-year disease-free survival rates were 66.7% in group I, 83.9% in group II, 8.3% in group III, and 64.0% in group IV (p < 0.0001). Thus, patients in group III exhibited the most unfavorable prognoses for recurrence. In multivariate analysis, the combined evaluation of VEGF-D expression and FDG uptake was an independent parameter for post-operative recurrence (p = 0.018). Conclusion A combination of low VEGF-D expression and high FDG uptake may be a biological indicator of lymph node metastasis and post-operative recurrence in patients with lung adenocarcinoma.
引用
收藏
页码:533 / 540
页数:8
相关论文
共 39 条
  • [31] Prognostic assessment of 18F-FDG uptake using dual point imaging and partial volume correction in resected non-small cell lung cancer patients
    Kaida, H.
    Azuma, K.
    Kawahara, A.
    Takamori, S.
    Akiba, J.
    Fujimoto, K.
    Axel, R.
    Ishii, K.
    Murakami, T.
    Ishibashi, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S668 - S669
  • [32] Prognostic impact of F-18-FDG uptake on PET in non-small cell lung cancer patients with postoperative recurrence following platinum-based chemotherapy
    Kaira, Kyoichi
    Yamamoto, Nobuyuki
    Kenmotsu, Hirotsugu
    Murakami, Haruyasu
    Ono, Akira
    Naito, Tateaki
    Endo, Masahiro
    Takahashi, Toshiaki
    RESPIRATORY INVESTIGATION, 2014, 52 (02) : 121 - 128
  • [33] Prognostic PET 18F-FDG Uptake Imaging Features Are Associated with Major Oncogenomic Alterations in Patients with Resected Non-Small Cell Lung Cancer (vol 72, pg 3725, 2012)
    Nair, V. S.
    Gevaert, O.
    Davidzon, G.
    Napel, S.
    Graves, E. E.
    Hoang, C. D.
    CANCER RESEARCH, 2012, 72 (18) : 4870 - 4871
  • [34] The maximum standardized uptake value 18F-FDG PET is independent of the immunohistochemical expression of platelet derived endothelial growth factor in patients with non-small cell lung cancer
    Ruibal, Alvaro
    Abdulkader, Ihab
    Gude, Francisco
    Leon, L.
    MEDICINA CLINICA, 2009, 132 (16): : 645 - 646
  • [35] Prognostic value of 2-[18F]fluoro-2-deoxy-D-glucose uptake as measured by PET scan in patients with non-small cell lung cancer
    Chen, Xiang
    Zhao, Jun
    Guan, Yi-Hui
    Lu, Shun
    Zuo, Chuan-Tao
    Hua, Feng-Chun
    Lin, Xiangtong
    MOLECULAR MEDICINE REPORTS, 2008, 1 (06) : 889 - 893
  • [36] Value of dual time point F-18 FDG-PET/CT imaging for the evaluation of prognosis and risk factors for recurrence in patients with stage I non-small cell lung cancer treated with stereotactic body radiation therapy
    Satoh, Yoko
    Nambu, Atsushi
    Onishi, Hiroshi
    Sawada, Eiichi
    Tominaga, Licht
    Kuriyama, Kengo
    Komiyama, Takafumi
    Marino, Kan
    Aoki, Shinichi
    Araya, Masayuki
    Saito, Ryo
    Maehata, Yoshiyasu
    Oguri, Mitsuhiko
    Araki, Tsutomu
    EUROPEAN JOURNAL OF RADIOLOGY, 2012, 81 (11) : 3530 - 3534
  • [37] Metabolic features measured on 18F-FDG PET and aerogenous spread are prognostic factors for disease-free survival in early stage non-small cell lung cancer patients treated by curative surgical resection without adjuvant therapy
    Kang, Y.
    Song, Y.
    Lee, W.
    Kim, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S677 - S677
  • [38] Standardized Uptake Values Derived from 18F-FDG PET May Predict Lung Cancer Microvessel Density and Expression of KI 67, VEGF, and HIF-1α but Not Expression of Cyclin D1, PCNA, EGFR, PD L1, and p53
    Surov, Alexey
    Meyer, Hans Jonas
    Wienke, Andreas
    CONTRAST MEDIA & MOLECULAR IMAGING, 2018,
  • [39] Prognostic value of combining clinical factors, 18F-FDG PET-based intensity, volumetric features, and deep learning predictor in patients with EGFR-mutated lung adenocarcinoma undergoing targeted therapies: a cross-scanner and temporal validation study
    Lue, Kun-Han
    Chen, Yu-Hung
    Chu, Sung-Chao
    Lin, Chih-Bin
    Wang, Tso-Fu
    Liu, Shu-Hsin
    ANNALS OF NUCLEAR MEDICINE, 2024, 38 (08) : 647 - 658